Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | GPR4 | P46093 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30224999 | 1.00 | PTGER4 (0.55) | PTGER4TAAR1CYP1A2CYP2A6GPR4 | |
| Hydrochloric Acid SCHEMBL1999779 | 0.99 | PTGER4 (0.54) | PTGER4TAAR1CYP1A2CYP2A6GPR4 | |
| SCHEMBL23876875 | 0.93 | PTGER4 (0.51) | PTGER4TAAR1CYP1A2CYP2A6HTR2A | |
| SCHEMBL1625727 | 0.90 | PTGER4 (0.47) | PTGER4HTR2AGRM5GRM1 | |
| SCHEMBL21741607 | 0.90 | PTGER4 (0.57) | PTGER4CYP1A2GPR4FAAHGRM5 | |
| SCHEMBL1625376 | 0.88 | PTGER4 (0.44) | PTGER4TAAR1CYP1A2CYP2A6BACE1 | |
| SCHEMBL1624736 | 0.87 | PTGER4 (0.57) | PTGER4GPR4FAAHGRM5GRM1 | |
| SCHEMBL30513699 | 0.87 | PTGER4 (0.57) | PTGER4GPR4FAAHGRM5GRM1 | |
| SCHEMBL1624672 | 0.87 | PTGER4 (0.55) | PTGER4GPR4FAAHGRM5GRM1 | |
| SCHEMBL23876548 | 0.87 | PTGER4 (0.42) | PTGER4TAAR1CYP1A2CYP2A6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496274-A | Preparation method of EP4 receptor antagonist | 江苏天和制药有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| CN-116496274-A | Preparation method of EP4 receptor antagonist | 江苏天和制药有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496274-A | Preparation method of EP4 receptor antagonist | 江苏天和制药有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023012820-A1 | A PROCESS FOR THE PREPARATION OF GRAPIPRANT AND ITS INTERMEDIATES | ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | disclosed |
| US-11254675-B2 | Process for preparation of grapiprant | CADILA HEALTHCARE LIMITED (IN) | 2022-02-22 | — | — | US | disclosed |
| US-20210353648-A1 | GRAPIPRANT UNIT DOSAGE FORMS | ASKAT INC. (JP) | 2021-11-18 | — | — | US | disclosed |
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | CADILA HEALTHCARE LIMITED (IN) | 2021-11-11 | — | — | US | disclosed |
| US-20210300921-A1 | EP4 INHIBITORS AND SYNTHESIS THEREOF | ASKAT INC. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | ASKAT INC. (JP) | 2021-09-23 | — | — | US | disclosed |
| CN-1658847-A | Use of EP4 receptor ligands for the treatment of IL-6 related disorders | PFIZER (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300921-A1 | EP4 INHIBITORS AND SYNTHESIS THEREOF | PTGER4, EPB41, CDK4 | PTGER4 1/4885TAAR1 2971/4885CYP1A2 2507/4885 |
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885TAAR1 4165/4885CYP1A2 3102/4885 |
| US-20210353648-A1 | GRAPIPRANT UNIT DOSAGE FORMS | GHSR, GHRHR, SLC6A4 | PTGER4 51/4885TAAR1 645/4885CYP1A2 694/4885 |
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | ADCYAP1R1, GANC, DRD4 | PTGER4 271/4885TAAR1 887/4885CYP1A2 266/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885TAAR1 2192/4885CYP1A2 139/4885 |
| US-11254675-B2 | Process for preparation of grapiprant | ADCYAP1R1, GANC, DRD4 | PTGER4 271/4885TAAR1 887/4885CYP1A2 266/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | PTGER4 1/4885TAAR1 763/4885CYP1A2 1118/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 55/4885TAAR1 2216/4885CYP1A2 144/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885TAAR1 493/4885CYP1A2 1271/4885 |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | PTGER4 1/4885TAAR1 4165/4885CYP1A2 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.